mutares AG acquires STADA Production Ireland Ltd. (“SPI”)

mutares AG, Munich, has taken over STADA Production Ireland Ltd. (SPI), a contract manufacturer of pharmaceutical drugs based in Clonmel/ Ireland, from STADA Arzneimittel AG, a German MDAX-listed company on February 06, 2012. SPI generated in 2011 a turnover of approximately EUR 28 million with production and packaging of tablets and capsules and employs about 180 people.

SPI has been producing drugs in Clonmel since 1984 and holds licenses (FDA, EU GMP) for the production of a wide range of different pharmaceuticals, including antibiotics, for the European and the US market. The STADA Group is selling SPI with the objective to focus its world-wide production capacities. Based on contract manufacturing agreements SPI will continue to be a supplier for STADA for a transitional period.

Dr. Axel Geuer, member of the executive board and founder of mutares AG, says with a view to the future development of the company: „With a production capacity of 1.6 million tablets and capsules a year and a number of different production methods and packaging techniques, SPI is well positioned to acquire new customers and to further expand its business. We are looking forward to accompanying this growth strategy.“

About STADA Arzneimittel AG:

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA’s business model focuses on the health care market. At the center of the internationally oriented business activities are the pharmaceutical and, in particular, the generics market with sustainable growth potential. As a globally leading generics producer, STADA has a traditionally strong presence in Europe and is the clear number 3 in Germany. In financial year 2010, STADA achieved Group sales of EUR 1,627.0 million, earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 268.8 million and net income of EUR 68.4 million. As of December 31, 2010, STADA employed a total of 8,024 people.